New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2013
08:42 EDTCCXIChemoCentryx completes target enrollment of CCX140 Phase II trial
ChemoCentryx announced that it has completed the target enrollment of 270 patients in a Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2 and the Company's lead wholly owned drug candidate. Enrollment will be closed by June 30, 2013, at which time ChemoCentryx expects total enrollment to exceed 300 patients in the randomized, double-blind, placebo-controlled study.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
13:04 EDTCCXIOn The Fly: Midday Wrap
Subscribe for More Information
09:13 EDTCCXIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Adobe (ADBE), up 5.5% after reporting first quarter results and that it will acquire Fotolia for approximately $800 in cash. ALSO HIGHER: ChemoCentryx (CCXI), up 107.1% after Phase II clinical trial in diabetic nephropathy with CCX140 met its primary endpoint... Oncothyreon (ONTY), up 15.8% after announcing exclusive agreement with Array BioPharma (ARRY)... Talisman Energy (TLM), up 24.4% after a report that Repsol (REPYY) is preparing to make a C$6.00 per share bid... GoPro (GPRO), up 4.4% after being upgraded to Overweight from Neutral at JPMorgan. LOWER: Emerald Oil (EOX), down 18% after cutting fiscal 2015 guidance, naming new COO, and providing an updated fiscal 2015 development plan... Goodrich Petroleum (GDP), down 8.2% after being downgraded to Underweight from Overweight at JPMorgan... MEI Pharma (MEIP), down 3.9% after 10M share Secondary priced at $4.00... Heritage-Crystal Clean (HCCI), down 6.6% after 3.1M share Secondary priced at $10.00.
09:03 EDTCCXIChemoCentryx up 107.1% after Phase II trial met primary endpoint
Subscribe for More Information
06:46 EDTCCXIChemoCentryx to host conference call
Subscribe for More Information
06:38 EDTCCXIChemoCentryx reports Phase II nephropathy with CCX140 trial met primary endpoint
Subscribe for More Information
December 4, 2014
08:33 EDTCCXIChemoCentryx granted EU orphan drug designation for CCX168
ChemoCentryx reported today the European Commission has granted orphan medicinal product designation for CCX168, an orally administered inhibitor targeting the receptor for the complement protein known as C5a, for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis. Both conditions are forms of anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use